Loading...
•
Mar 31, 2020
Surmodics Q2 2020 Earnings Report
Surmodics reported a 1% increase in revenue year-over-year and GAAP EPS of $0.11.
Key Takeaways
Surmodics, Inc. reported a slight increase in revenue for the second quarter of fiscal year 2020, with a 1% increase year-over-year. GAAP EPS was $0.11, while non-GAAP EPS was $0.04. The company has suspended its financial guidance for fiscal year 2020 due to the uncertainty surrounding the COVID-19 pandemic.
Total revenue for the second quarter of fiscal 2020 was $22.8 million, compared to $22.7 million in the prior-year period.
GAAP EPS was $0.11, while non-GAAP EPS was $0.04.
Medical Device revenue was $16.3 million, a decrease of 6% year-over-year, impacted by patent expiration and COVID-19 related procedure postponements.
In Vitro Diagnostics revenue was $6.5 million, an increase of 21% year-over-year.
Surmodics
Surmodics
Surmodics Revenue by Segment
Revenue by Segment
Medical Device Revenue
CapyFin.comIn Vitro Diagnostics Revenue
CapyFin.com Forward Guidance
Due to the uncertainty surrounding the duration and magnitude of the COVID-19 pandemic, Surmodics is suspending the previously issued financial guidance for fiscal year 2020.
Revenue & Expenses
Visualization of income flow from segment revenue to net income